United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2020_register
executive
2020-07-10
article
Prospective Grant of Exclusive Patent Commercialization License: N6, a Novel, Broad, Highly Potent HIV-Specific Antibody and a Broadly Neutralizing Human Anti-HIV Monoclonal Antibody (10E8) Capable of Neutralizing Most HIV-1 Strains
Notices
D09002ee1bdb54a18
D09002ee1bdb54acb
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
National Institutes of Health
originator
org
United States Government Agency or Subagency
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent commercialization license to RNAceuticals, Inc. located at 12 Indian Trail Road, Woodbridge, CT, USA to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.
85 FR 41607
https://www.govinfo.gov/app/details/FR-2020-07-10/2020-14836
2020-14836
fr10jy20-123
4140-01-P
https://www.govinfo.gov/app/details/FR-2020-07-10/2020-14836
https://www.govinfo.gov/content/pkg/FR-2020-07-10/html/2020-14836.htm
https://www.govinfo.gov/content/pkg/FR-2020-07-10/pdf/2020-14836.pdf
2 p.
41607
41608
85 FR 41607
Prospective Grant of Exclusive Patent Commercialization License: N6, a Novel, Broad, Highly Potent HIV-Specific Antibody and a Broadly Neutralizing Human Anti-HIV Monoclonal Antibody (10E8) Capable of Neutralizing Most HIV-1 Strains; Federal Register Vol. 85, Issue
NOTICE
2020-14836
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
2020-07-27
4140-01-P
2020-14836
Notice.
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent commercialization license to RNAceuticals, Inc. located at 12 Indian Trail Road, Woodbridge, CT, USA to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.
Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, on or before July 27, 2020 will be considered.
Prospective Grant of Exclusive Patent Commercialization License:
N6, A Novel, Broad, Highly Potent HIV-Specific Antibody and A Broadly Neutralizing Human Anti-HIV Monoclonal Antibody (10E8) Capable of Neutralizing Most HIV1 Strains,
chris.kornak@nih.gov
Federal Register
Vol. 85, no. 133
Office of the Federal Register, National Archives and Records Administration
2020-07-10
continuing
daily
deposited
born digital
595 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2020-07-10
P0b002ee1a75faa36
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr10jy20
https://www.govinfo.gov/app/details/FR-2020-07-10
https://www.govinfo.gov/content/pkg/FR-2020-07-10/pdf/FR-2020-07-10.pdf
https://www.govinfo.gov/content/pkg/FR-2020-07-10/xml/FR-2020-07-10.xml
fdlp
41321
41904
DGPO
2020-07-10
2023-04-27
FR-2020-07-10
machine generated
eng
FR
FR-2020-07-10
85
133